🇸🇮 Medical cannabis in Slovenia

C moving towards B — today only cannabinoid medicines and pharmacy-compounded THC/CBD preparations are prescribable (cannabis flower stays a Group I prohibited drug); a new Zakon o konoplji za medicinske in znanstvene namene (ZKMZN, Act on cannabis for medical and scientific purposes) exists, but its medical-use implementing rules were not found on official pages.

The regulatory basis today is the Zakon o proizvodnji in prometu s prepovedanimi drogami (ZPPPD, Act on the production of and trade in illicit drugs) with the Uredba o razvrstitvi prepovedanih drog (Decree classifying illicit drugs; Uradni list RS 45/14, 22/16, 14/17), which places cannabis in Group I (no medical use) and cannabinoid preparations (THC, extracts, Sativex, nabilone) in Group II (prescribable by doctors on a narcotic prescription), and the Zakon o zdravilih (ZZdr-2, Medicines Act) with the Pravilnik o razvrščanju, predpisovanju in izdajanju zdravil. JAZMP (Javna agencija RS za zdravila in medicinske pripomočke, medicines agency) licenses import/export of Group II/III substances. The ZKMZN is listed on gov.si (Zdravstveni inšpektorat legislation page, PISRS id ZAKO9256) together with one implementing act, the Pravilnik o pogojih za pridobitev dovoljenja za proizvodnjo, promet in posedovanje konoplje za znanstvene namene (conditions for licences for scientific purposes); no pravilnik on prescribing/dispensing for medical use appears on the Ministry of Health legislation list (updated 25.8.2026) or JAZMP's legislation page. The law text (PISRS) could not be opened, so its Uradni list citation, entry into force and transitional deadlines are not verified.

Source: GOV.SI — Zdravstveni inšpektorat RS: Zakonodaja (health inspectorate legislation list; entry ZKMZN with PISRS link) · read 27 September 2026

Cannabis for medical purposes may be prescribed as an authorised medicine, a magistral (pharmacy-compounded) medicine or a galenic medicine. In practice the national medicines database lists only a handful of compounded THC/CBD and CBD oral solutions plus one authorised product, Epidyolex; there is no cannabis flower product on it at all.

ZKMZN, 25. člen (1): "Konoplja za medicinske namene v obliki zdravil, magistralnih zdravil in galenskih zdravil se lahko po strokovni presoji zdravnika predpiše za katerokoli indikacijo ali stanje" ("Cannabis for medical purposes in the form of medicines, magistral medicines and galenic medicines may, in the professional judgement of a doctor, be prescribed for any indication or condition"). Centralna baza zdravil (CBZ), checked 6 September 2026 (data refreshed 6.9.2026 02:42), holds magistral oral solutions under national codes 603430 (THC:CBD 8,3/8,3 mg per ml), 603443 (8,3/16,7 mg per ml), 603596 (2,0/20 mg per ml), 603582 (1,0/20 mg per ml), 603579 (0,5/15 mg per ml) and CBD-only solutions 603397, 603409, 603412, all ATC N03AX24, all "Magistralno zdravilo"; plus Epidyolex 100 mg/ml (158835, 158837, Rp/Spec, Jazz Pharmaceuticals Ireland Ltd). A CBZ full-text search for "konoplj" returned 0 records. Domestic cultivation is permitted but only industrially: ZKMZN 10. člen allows any variety of Cannabis sativa L. to be produced under a JAZMP licence, 11. člen requires closed, technically secured premises under GACP/GMP and European Pharmacopoeia quality standards, and 12. člen reserves licences to JAZMP applicants. Home or patient cultivation is not permitted anywhere in the Act.

Source: Zakon o konoplji za medicinske in znanstvene namene (ZKMZN), Uradni list RS, št. 60/2025, 25. in 10.–12. člen · read 6 September 2026

Any doctor, on their own professional judgement, for any indication or condition. There is no specialist gatekeeper, no approved-indication list and no registration or training requirement for the prescriber. A medical examination is required before the first prescription and again every 12 months.

ZKMZN, 25. člen (1): "Zdravnik lahko posameznemu pacientu prvič predpiše konopljo za medicinske namene na recept šele po predhodnem zdravniškem pregledu. Po preteku 12 mesecev od zadnjega zdravniškega pregleda je treba za nadaljnje predpisovanje konoplje za medicinske namene ponovno opraviti zdravniški pregled." ("A doctor may prescribe cannabis for medical purposes to an individual patient for the first time only after a prior medical examination. After 12 months have passed since the last medical examination, a further medical examination must be carried out for continued prescribing.") Veterinarians may prescribe for animals: 24. člen (2) refers to dispensing "na zdravniški ali veterinarski recept". The Zdravniška zbornica Slovenije objected on the day the law took effect, in a response to the Slovenska tiskovna agencija reported by RTV SLO and N1 — not in a notice on its own site — that the law, with this provision, "v slovenski pravni red vnesel anomalijo" ("introduced an anomaly into the Slovenian legal order") and that "Ni jim namreč znano, da bi za katero drugo zdravilo oziroma učinkovino zakon določal možnost predpisovanja za katerokoli indikacijo ali stanje" ("they are not aware of any other medicine or active substance for which the law provides the possibility of prescribing for any indication or condition"), adding "Pri tem po naši oceni ni videti stvarnega oziroma razumnega razloga" ("in our assessment there appears to be no substantive or reasonable ground for this").

Source: ZKMZN, Uradni list RS, št. 60/2025, 25. člen · read 6 September 2026

An ordinary non-renewable prescription (neobnovljivi recept) — expressly not a narcotics prescription. Each patient may receive at most one month's treatment per month. On dispensing, the pharmacy gives the patient a certificate proving lawful possession, valid for one month.

ZKMZN, 25. člen (2): "Konoplja za medicinske namene v obliki zdravil, magistralnih zdravil ali galenskih zdravil se predpiše na neobnovljivi recept, pri čemer se ne uporabljajo pravila za predpisovanje zdravil na poseben zdravniški recept iz predpisa, ki ureja razvrščanje, predpisovanje in izdajanje zdravil za uporabo v humani medicini." ("...is prescribed on a non-renewable prescription, whereby the rules for prescribing medicines on a special medical prescription under the regulation governing the classification, prescribing and dispensing of medicines for human use do not apply.") This is the operative liberalisation: it disapplies the special duplicate narcotics prescription that governed cannabinoid prescribing before. 25. člen (1) caps supply: "vendar posameznemu pacientu vsak mesec največ za enomesečno zdravljenje". 25. člen (3): "se v lekarni ob izdaji na zdravniški recept izda potrdilo, s katerim pacient izkazuje upravičenost do posedovanja in uporabe konoplje za medicinske namene pred organi nadzora. Potrdilo je veljavno en mesec od datuma izdaje." Slovenian media and the Ministry describe this in practice as a "zeleni ali beli recept" — a green form where the cost falls on compulsory health insurance, a white form where the patient self-pays. Note a live inconsistency: CBZ entries for the THC:CBD magistral solutions still carry the field "Izdaja na posebni zdravniški recept" (last changed 28.02.2023), which ZKMZN 25. člen (2) has overridden but which has not been updated in the database as of 6 September 2026.

Source: ZKMZN, Uradni list RS, št. 60/2025, 25. člen (2) in (3) · read 6 September 2026

No published rule permits or forbids prescribing medical cannabis remotely. The only binding constraint is that a medical examination must precede the first prescription and be repeated every 12 months; the law does not say whether that examination may be conducted remotely.

ZKMZN, 25. člen (1) requires a "predhodni zdravniški pregled" before the first prescription and a repeat examination after 12 months, but the Act contains no definition of how that examination must be conducted and no reference to telemedicine, telezdravje or remote consultation anywhere in its 55 articles. Slovenia has no cannabis-specific telemedicine regulation, and no general norm was found that authorises or prohibits remote prescribing of this class of preparation. Treat this as genuinely unsettled rather than permitted: a patient should not assume a remote-only consultation satisfies the 25. člen examination requirement.

Source: ZKMZN, Uradni list RS, št. 60/2025, 25. člen (1) · read 6 September 2026

Only pharmacies may dispense, on a doctor's or veterinarian's prescription. But the supply chain is still being built: the national medicines database contains no cannabis flower or herbal cannabis product at all, only compounded cannabinoid oral solutions, and there is no public evidence that JAZMP has yet licensed any producer or wholesaler under the new Act.

ZKMZN, 24. člen (1): "Promet na drobno s konopljo za medicinske namene v obliki zdravil, magistralnih zdravil in galenskih zdravili z vsebnostjo kanabinoidov lahko opravljajo samo izvajalci lekarniške dejavnosti"; 24. člen (2): "Konoplja za medicinske namene se izdaja samo v lekarnah na zdravniški ali veterinarski recept." Wholesale is restricted to licensed medicines or active-substance wholesalers (23. člen), and production and trade require a JAZMP licence valid 15 years (12., 16. člen), with quantities capped by JAZMP's annual strategic plan (16. člen (4)). As of 6 September 2026 a full-text search of Centralna baza zdravil for "konoplj" returns 0 records, and JAZMP's own cannabis section publishes no list of licence holders and no statement that any licence has been issued — even though 16. člen (6) requires JAZMP to publish holders' data on its website. JAZMP's patient-facing page "Dostop do zdravil s kanabinoidi" was last updated 19 August 2025, the day before the Act took effect, and its Q&A page still describes the pre-Act special duplicate prescription and states that standardised flower extract and dried flower "še ni vpeljano v rutinsko uporabo" ("has not yet been introduced into routine use"). What a Slovenian pharmacy can realistically supply today is a magistral oral solution it compounds itself.

Source: ZKMZN, Uradni list RS, št. 60/2025, 23.–24. člen; Centralna baza zdravil (MZ, JAZMP, ZZZS, NIJZ), search "konoplj" = 0 records · read 6 September 2026

Partial and narrow. Compounded cannabinoid oral solutions are on the ZZZS positive list (Lista P*) and so can be covered by compulsory health insurance — but only on the proposal of a named specialist and only once every other drug option is exhausted. Epidyolex is not classified on any ZZZS list.

Centralna baza zdravil records for the magistral cannabinoid oral solutions show "Na listo ZZZS — Lista: P*", last changed 08.12.2023, "Velja od: 01.01.2024". The prescribing restrictions attached to code 603430 (THC:CBD 1:1) are: "1. Za lajšanje onkološke bolečine v paliativnem podpornem zdravljenju, pri kateri so izčrpani vsi drugi farmakološki pristopi; le na predlog onkologa ali anesteziologa. 2. Za slabo obvladano kronično nevropatsko bolečino... le na predlog nevrologa ali specialista v protibolečinski ambulanti. 3. Za zdravljenje refraktarne bolečine in spastičnosti pri odraslih bolnikih z multiplo sklerozo... le na predlog nevrologa s poglobljenim znanjem na področju multiple skleroze. 4. Za zdravljenje spastičnosti in hude nevrološke ali onkološke bolečine v paliativni oskrbi otrok... le na predlog pediatra ali otroškega nevrologa tercialne ustanove." Code 603596 (THC:CBD 1:10) is restricted to refractory childhood epilepsy/encephalopathy on the proposal of a tertiary paediatric neurologist, and to spasticity in paediatric palliative care. This is the practical shape of the anomaly the Medical Chamber complained about: the Act lets any doctor prescribe for any condition, but the ZZZS listing that decides who pays was set in 2023 and still funnels every reimbursed prescription through a specialist's proposal. Outside those indications, the prescription is a white (self-pay) one. ZZZS also warns that magistral medicines prescribed outside the listed form are not a right under compulsory insurance and are dispensed as self-pay: "neustrezno predpisana magistralna zdravila... niso več pravica iz OZZ in se jih v lekarnah izda kot samoplačniška."

Source: Centralna baza zdravil, zdravilo Kanabinoidna 8,3 mg/8,3 mg v 1 ml (THC:CBD 1:1), nacionalna šifra 603430 — razvrstitev na listo ZZZS · read 6 September 2026

No price is published for any cannabis preparation in Slovenia. The national medicines database carries no regulated price, no agreed price and no maximum recognised value for the compounded cannabinoid solutions, so what a self-paying patient is charged depends on the individual compounding pharmacy and is not publicly knowable in advance.

In Centralna baza zdravil the price block for each cannabinoid magistral preparation (checked for national codes 603430, 603443, 603596 on 6 September 2026) is empty: "Regulirana cena" — no value; "Dogovorjena cena" — no value; "Najvišja priznana vrednost zdravila/živila (NPV): -"; "Informativno doplačilo" — no value. This is normal for magistral medicines, which are priced per preparation by the pharmacy that compounds them rather than carrying a national list price. No official published figure for a monthly course was found on ZZZS, JAZMP or Ministry of Health sources. Any euro figure circulating for Slovenia should be treated as unsourced.

Source: Centralna baza zdravil, Cene zdravila block for nacionalna šifra 603443 — all price fields empty, NPV "-" · read 6 September 2026

Do not drive. Slovenia has no numeric THC limit — the offence is driving while a test detects the substance in blood or saliva, and prescribed psychoactive medicines are expressly covered. A prescription opens a route — a control medical examination that can find you used the medicine as instructed — but for the THC solutions the instruction on record is an absolute driving ban, so in practice that route is closed. The THC-containing preparations are flagged in the national database with the triangle marking, meaning an absolute prohibition on operating vehicles.

Zakon o pravilih cestnega prometa (ZPrCP), 106. člen (prepovedane droge, psihoaktivna zdravila in druge psihoaktivne snovi), (1): "Voznik ne sme voziti vozila v cestnem prometu niti ga začeti voziti, če je pod vplivom prepovedanih drog, psihoaktivnih zdravil ali drugih psihoaktivnih snovi, in njihovih presnovkov." (2): "Pod vplivom snovi iz prejšnjega odstavka je voznik... pri katerem se s posebnimi sredstvi, napravami ali s strokovnim pregledom ugotovi prisotnost takih snovi v krvi ali slini." — i.e. the test is presence, not a threshold. (3): "Z globo najmanj 1.200 eurov se kaznuje za prekršek voznik..." plus 18 penalty points (18 kazenskih točk), which in Slovenia is enough to lose the licence. (4) provides that if the substance or its metabolites are found only in urine, the driver is referred for a control examination rather than fined. (5) is the provision a patient needs to know: where psychoactive medicines are found in blood or saliva the driver is sent to a control medical examination, and "se šteje, da voznik ... ni pod vplivom psihoaktivnih zdravil, če se s kontrolnim zdravstvenim pregledom ugotovi, da je ... uporabljal psihoaktivna zdravila v skladu s predpisano terapijo in navodilom lečečega zdravnika" — so a prescription is a route to a defence, not a defence in itself, and it works only if the medicine was used as instructed. For the THC solutions the instruction on record is an absolute driving ban (next sentence), which closes that route in practice; and whether a magistral THC preparation is a "psihoaktivno zdravilo" or a "prepovedana droga" for the purposes of (5) is not settled in the text. Separately, Centralna baza zdravil marks the THC:CBD magistral solutions with "Trigonik (absolutna prepoved upravljanja vozil)" — the red-triangle packaging marking denoting an absolute ban on operating vehicles. The certificate a pharmacy issues under ZKMZN 25. člen (3) proves lawful possession before enforcement authorities; it does not protect against the driving offence.

Source: Zakon o pravilih cestnega prometa (ZPrCP-UPB2), 106. člen · read 6 September 2026

To carry prescribed cannabis across Schengen borders you need a certificate under Article 75 of the Schengen Convention, issued or authenticated by the competent authority of your country of residence. Slovenia does not publish which body issues or authenticates it — that must be confirmed with JAZMP or the Ministry of Health before travelling.

The Financial Administration (FURS) states the requirement without naming the Slovenian issuing body: "Te osebe morajo imeti potrdilo, ki ga je izdal ali overil pristojni organ države njihovega stalnega prebivališča." ("These persons must have a certificate issued or authenticated by the competent authority of their country of permanent residence.") JAZMP's pages on import and export of group II and III prohibited drugs address business licences only and say nothing about patient travel certificates; ZKMZN contains no travel provision. Do not confuse the Schengen certificate with the domestic "potrdilo" under ZKMZN 25. člen (3): that one is issued by the dispensing pharmacy, is valid one month, and evidences lawful possession before Slovenian enforcement authorities only. The issuing authority for the Article 75 certificate in Slovenia could not be verified from a public primary source on 6 September 2026.

Source: Finančna uprava RS (FURS), Vnos zdravil · read 6 September 2026

A visitor may be prescribed cannabinoid medicines by a Slovenian doctor (no residency bar is published), but flower is not prescribable to anyone today. EU prescriptions for these narcotic medicines are unlikely to be filled because Directive rules let Slovenia exclude special (narcotic) prescriptions and Slovenia's own rule could not be verified. For travel, Schengen residents use the Article 75 certificate (up to 30 days); who issues it in Slovenia and the rules for non-Schengen visitors were not found on official pages.

1. Non-residents: no official page addresses foreign patients; prescribing follows ZZdr-2 and the Pravilnik o razvrščanju, predpisovanju in izdajanju zdravil (narcotic prescription for Group II substances) — 'not published'. 2. Prescriptions from another EU state: Directive 2011/24/EU Art. 11(1) recognition applies, Art. 11(6) allows exclusion of 'medicinal products subject to special medical prescription'; the Slovenian transposition (ZZdr-2 / Pravilnik) could not be opened (PISRS JavaScript), so whether Slovenia excludes narcotic prescriptions is 'not published' here; Slovenia is connected to the EU cross-border e-prescription service only for ordinary medicines. 3. Bringing medicine in: JAZMP's illicit-drugs pages cover only business import/export licences for Group II/III substances and explicitly do not address travellers; the gov.si 'prepovedane droge' theme page and search return no traveller certificate page — issuing authority for the Schengen Art. 75 certificate and any non-Schengen quantity/day rule: 'not published' on the pages opened. Cannabis flower remains a Group I drug, so bringing flower into Slovenia is not covered by any personal-use allowance found. 4. Foreign telemedicine prescriptions: as 2 — not verifiable; no official statement.

Source: JAZMP — Prepovedane droge (illicit drugs: classification, licences; no traveller rules) · read 27 September 2026

Slovenia has adopted a dedicated cannabis-for-medical-and-scientific-purposes act (ZKMZN) but, as far as official pages show, only the scientific-use licensing rules have been issued; the medical-use rules (who prescribes, which products, JAZMP procedures) are still to come and no date is published.

Official evidence found: the ZKMZN (Zakon o konoplji za medicinske in znanstvene namene) is listed on the gov.si health-inspectorate legislation page (PISRS ZAKO9256) with one subordinate act, 'Pravilnik o pogojih za pridobitev dovoljenja za proizvodnjo, promet in posedovanje konoplje za znanstvene namene' (PRAV16017); gov.si search shows the law cited in a Government session record of November 2025 (180. seja vlade) which could not be read. The Ministry of Health legislation page (updated 25.8.2026) and JAZMP's 'Predpisi' page still list only ZPPPD, ZPUPD, the classification decree and ZZdr-2 — no medical-cannabis pravilnik. Therefore: adopted law, scientific-use rules issued, medical-use implementation pending with no published timetable. Uradni list citation and entry-into-force date of ZKMZN: not verified (PISRS and Uradni list search are not readable by this tool).

Source: GOV.SI — Ministrstvo za zdravje: Zakonodaja (Ministry of Health legislation list, updated 25.8.2026) · read 27 September 2026

No official figure exists. Neither NIJZ, ZZZS, JAZMP nor the Ministry of Health has published a count of patients or prescriptions for medical cannabis in Slovenia, before or since the 2025 Act.

NIJZ maintains a dedicated page on cannabinoid medicine prescribing and states plainly that it holds no prescription-count data: "...zato Nacionalni inštitut za javno zdravje podatkov o številu receptov nima." ("...therefore the National Institute of Public Health has no data on the number of prescriptions.") That page was last updated 16 December 2022. ZKMZN 16. člen (4) and 45. člen build JAZMP's annual strategic plan partly on NIJZ data about prescribed quantities of cannabinoid medicines, and JAZMP must report annually to the Ministry by 31 March — so a figure should eventually become public, but none had been published as of 6 September 2026. Any patient number quoted for Slovenia today is an estimate, not an official statistic.

Source: NIJZ, Predpisovanje zdravil iz kanabinoidov · read 6 September 2026